Bicara Therapeutics (BCAX) Other Operating Expenses (2023 - 2026)

Bicara Therapeutics has reported Other Operating Expenses for 4 years, with the latest figure at $47.4 million in Q1 2026.

• For the quarter ending Q1 2026, Other Operating Expenses rose 70.76% year-over-year to $47.4 million; the trailing twelve-month figure through Mar 2026 stood at $47.4 million (up 31.78% YoY), and the FY2024 full-year result was $8.2 million, up 48229.41% from the prior year.
• Other Operating Expenses for Q1 2026 stood at $47.4 million, up from -$6000.0 in the prior quarter.
• The five-year high for Other Operating Expenses was $47.4 million in Q1 2026, with the low at -$36000.0 in Q3 2024.
• Historically, Other Operating Expenses has averaged $7.6 million across 4 years, with a median of $39000.0 in 2023.
• Annual changes were most pronounced in 2024 — Other Operating Expenses sank 192.31% — and 2025, when it jumped 86643.75%.
• Bicara Therapeutics' Other Operating Expenses stood at $62000.0 in 2023, then surged by 13093.55% to $8.2 million in 2024, then slumped by 100.07% to -$6000.0 in 2025, then jumped by 790100.0% to $47.4 million in 2026.
• The last three Other Operating Expenses figures came in at $47.4 million (Q1 2026), -$6000.0 (Q4 2025), and -$25000.0 (Q3 2025), per Business Quant data.